Effects of Peppermint Oil in Mild-moderate Hypertension.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-01

Study Completion Date

2025-08-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiovascular and associated hypertensive diseases are the leading health burden and cause of mortality worldwide; therefore, the necessity for effective interventions is paramount. Dietary interventions to improve cardiovascular health are highly sought after as they possess less risk and financial burden than pharmacological drugs. Our previous randomized trial has shown that oral peppermint can improving systolic blood pressure and other cardiovascular/ blood lipids in healthy individuals. However, to date, no research has explored this using a placebo randomized intervention in patients with hypertension.

Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in participants with mild-moderate hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Standardized Eucommia Extract in the Treatment of Hypertension

NCT00626132

Hypertension

COMPLETED PHASE2

Effect of Hibiscus and Lippia Extract on Blood Pressure

NCT03507023

Blood Pressure

COMPLETED NA

Effect of Hibiscus Sabdariffa on Blood Pressure in a University Population

NCT03804801

Elevated Blood Pressure

UNKNOWN PHASE4

Olive Leaf Extracts in the Control of Hypertension

NCT05636826

Hypertension

RECRUITING PHASE2/PHASE3

The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension

NCT02156024

Masked Hypertension

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Identical in taste and colour to the supplement juice, but with no peppermint content.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Peppermint oil

50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.

Group Type EXPERIMENTAL

Peppermint oil

Intervention Type DIETARY_SUPPLEMENT

Peppermint oil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peppermint oil

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged from 18-65 years
2. Systolic blood pressure 120 to 139 mmHg
3. Not taking prescribed medicine for blood pressure management
4. have the ability to complete written questionnaires independently
5. Able to provide informed consent

Exclusion Criteria

1. diagnosed diabetes mellitus
2. known cardiovascular disease or clinically significant cardiovascular comorbidity, including coronary heart disease, symptomatic heart failure, clinically significant arrhythmia, or a history of stroke or transient ischaemic attack within the previous 6 months
3. known or suspected secondary hypertension, including renal, renovascular, or endocrine causes
4. known clinically significant renal impairment or severe hepatic disease
5. evidence or history of severe hypertension related target organ damage requiring specialist management
6. pregnant or lactating women
7. allergy to peppermint
8. habitual consumption of peppermint products
9. regular consumption of antioxidant supplements
10. body mass index larger than 40.0 kg/m²
11. current enrolment in other clinical trials or use of other external therapies likely to influence outcomes
12. condition(s) likely to compromise informed consent, protocol compliance, or outcome assessment, including severe psychiatric illness, cognitive impairment, or active substance or alcohol misuse.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No